Ribon Therapeutics to Present New Preclinical Data on its PARP7 Inhibitor – RBN-2397 – and its Discovery Platform at the Upcoming AACR 2020 Virtual Meeting II

RBN-2397 restores type I IFN signaling in the tumor, causes complete tumor regressions and adaptive immunity in preclinical models

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Ribon Therapeutics, a clinical stage oncology company developing first-in-class therapeutics targeting stress response pathways, today announced the presentation of new data at the upcoming American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting II, taking place from June 22-24, 2020.

Ribon will present findings from its development program, which includes the following:

• Title: PARP7 negatively regulates the Type I interferon response in cancer cells and its inhibition leads to tumor regression

Abstract ID: 3405

Session Type: Minisymposium (oral presentation)

Session Category: Experimental and Molecular Therapeutics

Session Title: Novel Mechanisms Enabled by Tool Molecules

Date/Time: June 23, 2020, 9:00 – 11:00 a.m. EDT

Presenter: Joseph Gozgit, PhD

• Title: A bespoke screening platform to study mono(ADP-ribosylation)

Abstract ID: 506 / 2

Session Type: Poster Session

Session Title: Screening, Lead Identification, and Optimization

Date/Time: June 22, 2020, 9:00 a.m. – 6:00 p.m. EDT

Presenter: Tim J. Wigle, PhD

• Title: A multi-omic characterization of PARP enzymes in cancer to identify novel monoPARP drug targets

Abstract ID: 4381

Session Type: Poster Session

Session Title: Knowledge, Networks, Graphs, and Models for Discovery

Date/Time: June 22, 2020, 9:00 a.m. – 6:00 p.m. EDT

Presenter: Ryan Abo, PhD

AACR Virtual Meeting II the second of two virtual meetings being held by AACR; the first, AACR Virtual Meeting I, took place April 27-28, 2020. Presentations from Virtual Meeting I can be accessed at https://ribontx.com/events/.

About Ribon Therapeutics

Ribon Therapeutics is a clinical stage biotechnology company developing first-in-class therapeutics targeting novel enzyme families activated under cellular stress conditions that contribute to disease. We are exploring novel areas of biology to develop effective treatments for patients with limited therapeutic options. Leveraging a chemical biology approach and our proprietary discovery platform, we are building a pipeline of selective, small molecule inhibitors to numerous NAD⁺ utilizing enzymes, beginning with monoPARPs, which have applications across multiple therapeutic areas. Our lead program is RBN-2397, a first-in-class PARP7 inhibitor in development for the treatment of cancer. Ribon is located in Cambridge, Massachusetts. For more information visit www.RibonTx.com

Contacts

Media:
Cory Tromblee

Scient PR

[email protected]